Similar to clinically used antidepressants, cannabinoids can also regulate anxiety and depressive symptoms.
Although the mechanisms of these effects are not completely understood, recent evidence suggests that changes in
endocannabinoid system could be involved in some actions of antidepressants. Chronic antidepressant treatment modifies
the expression of CB1 receptors and endocannabinoid (EC) content in brain regions related to mood and anxiety control.
Moreover, both antidepressant and cannabinoids activate mitogen-activated protein (MAP) kinase and phosphoinositide 3-
kinase(PI3-K)/Akt or PKB signaling, intracellular pathways that regulate cell proliferation and neural cell survival.
Facilitation of hippocampal neurogenesis is proposed as a common effect of chronic antidepressant treatment. Genetic or
pharmacological manipulations of cannabinoid receptors (CB1 and CB2) or enzymes responsible for endocannabinoidmetabolism
have also been shown to control proliferation and neurogenesis in the hippocampus. In the present paper we
reviewed the studies that have investigated the potential contribution of cannabinoids and neurogenesisto antidepressant
effects. Considering the widespread brain distribution of the EC system, a better understanding of this possible interaction
could contribute to the development of therapeutic alternatives to mood and anxiety disorders.
Keywords: Neurogenesis, antidepressant drugs, cannabinoids.
Rights & PermissionsPrintExport